Furthermore, the addition of anti-PD-1 antibody exhibited not only enhanced primary tumor control, but also a superior survival benefit with a 76% increase in median survival and approximately 60% decrease in pulmonary metastatic nodules. This evidence concerns the gene PDCD1 and neoplasm.